Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 93 results:
Συντάκτης Τίτλος [ Τύπος(Asc)] Έτος
Φίλτρα: Συντάκτης is Anastasilakis, Athanasios D  [Clear All Filters]
Journal Article
Anastasilakis, A. D., Polyzos S. A., Kitridis D., Makras P., Yavropoulou M. P., Palermo A., et al. (2021).  Ιrisin levels in postmenopausal women with an incident hip fracture.. Endocrine. 73(3), 719-722.
Anastasilakis, A. D., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Makras P. (2019).  Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.. J Bone Miner Res.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.. Support Care Cancer. 17(10), 1329-30.
Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. (2020).  The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.. Bone. 138, 115478.
Toulis, K. A., Goulis D. G., & Anastasilakis A. D. (2009).  Thiazolidinedione use and the risk of fractures.. CMAJ. 180(8), 841-2; author reply 842-3.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
Toulis, K. A., Anastasilakis A. D., Polyzos S. A., & Makras P. (2011).  Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis.. Hormones (Athens). 10(3), 174-95.
Polyzos, S. A., Perakakis N., Boutari C., Kountouras J., Ghaly W., Anastasilakis A. D., et al. (2019).  Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.. J Clin Endocrinol Metab.
Polyzos, S. A., & Anastasilakis A. D. (2010).  A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy.. World J Surg. 34(4), 844-51.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy.. J Otolaryngol Head Neck Surg. 39(5), 532-41.
Anastasilakis, A. D., Polyzos S. A., & Nikolopoulos P. (2008).  Subendothelial carotid hematoma after fine-needle aspiration biopsy of a solitary thyroid nodule.. J Ultrasound Med. 27(10), 1517-20.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
Gkiomisi, A., Makedou K. G., Anastasilakis A. D., Polyzos S. A., Kourtis A., Gerou S., et al. (2013).  Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum.. Cytokine. 61(1), 127-32.
Giomisi, A., Kourtis A., Toulis K. A., Anastasilakis A. D., Makedou K. G., Mouzaki M., et al. (2011).  Serum vaspin levels in normal pregnancy in comparison with non-pregnant women.. Eur J Endocrinol. 164(4), 579-83.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Kanakis G., Schini M., et al. (2012).  Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.. J Clin Endocrinol Metab. 97(4), E618-21.
Makras, P., Polyzos S. A., Anastasilakis A. D., Terpos E., Papatheodorou A., & Kaltsas G. A. (2012).  Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. Mol Ther. 20(1), 6-7.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Litsas I., Kita M., Panagiotou A., et al. (2010).  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.. J Bone Miner Metab. 28(3), 314-9.
Toulis, K. A., Anastasilakis A. D., Tzellos T. G., Goulis D. G., & Kouvelas D. (2010).  Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis.. Thyroid. 20(10), 1163-73.
Anastasilakis, A. D., Polyzos S. A., & Toulis K. A. (2011).  Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge.. Curr Opin Endocrinol Diabetes Obes. 18(6), 383-8.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Bisbinas I., Sakellariou G. T., Gkiomisi A., et al. (2012).  The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.. Clin Endocrinol (Oxf). 77(6), 816-22.
Makras, P., Yavropoulou M. P., Polyzos S. A., Papapoulos S. E., Georgakopoulou D., Papatheodorou A., et al. (2023).  The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.. Osteoporos Int.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., & Terpos E. (2009).  RANKL inhibition for the management of patients with benign metabolic bone disorders.. Expert Opin Investig Drugs. 18(8), 1085-102.
Anastasilakis, A. D., Trovas G., Balanika A., Polyzos S. A., Makras P., & Tournis S. (2020).  Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.. J Clin Densitom.
Polyzos, S. A., Anastasilakis A. D., Litsas I., Efstathiadou Z., Kita M., Arsos G., et al. (2010).  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.. J Bone Miner Metab. 28(6), 706-12.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.